Stephens & Co. Reiterates Overweight on Elevance Health, Maintains $615 Price Target
Portfolio Pulse from Benzinga Newsdesk
Stephens & Co. analyst Scott Fidel has reiterated an Overweight rating on Elevance Health (NYSE:ELV) and maintained a price target of $615.
June 11, 2024 | 12:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stephens & Co. analyst Scott Fidel has reiterated an Overweight rating on Elevance Health (NYSE:ELV) and maintained a price target of $615.
The reiteration of an Overweight rating and a high price target of $615 by a reputable analyst is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100